Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma
Conditions
Keywords
neoadjuvant therapy, radical nephroureterectomy, Tislelizumab, Cisplatin-ineligible
Brief summary
Neoadjuvant therapy of cisplatin-based chemotherapy has been proved to improve prognosis of muscle invasive UTUC patients in several studies. This study is designed to investigate the safety and efficacy of neoadjuvant PD-1 monoclonal antibody in patients with locally advanced upper urinary tract urothelial carcinoma (UTUC) which are ineligible for cisplatin. Tislelizumab, an anti-programmed death protein-1 (PD-1) monoclonal antibody, was engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. The safety, tolerability, and efficacy of tislelizumab in patients with PD-L1 positive urothelial carcinoma who progressed during/following platinum-containing therapy was proved in a phase 2 trial (CTR20170071). This trial focuses on the efficacy of Tislelizumab to induce pathological down-staging of locally advanced UTUC in neoadjuvant setting.
Detailed description
Neoadjuvant therapy of cisplatin-based chemotherapy has been proved to improve prognosis of muscle invasive UTUC patients in several studies. This study is designed to investigate the safety and efficacy of neoadjuvant PD-1 monoclonal antibody in patients with locally advanced upper urinary tract urothelial carcinoma (UTUC) which are ineligible for cisplatin. Tislelizumab, an anti-programmed death protein-1 (PD-1) monoclonal antibody, was engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. The safety, tolerability, and efficacy of tislelizumab in patients with PD-L1 positive urothelial carcinoma who progressed during/following platinum-containing therapy was proved in a phase 2 trial (CTR20170071). This trial focuses on the efficacy of Tislelizumab to induce pathological down-staging of locally advanced UTUC in neoadjuvant setting.
Interventions
DRUGTislelizumab
Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
Sponsors
RenJi Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) prior to surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 1\. had non-metastatic high risk UTUC and planed to receive surgery(defined as high grade UTUC either by endoscopic biopsy or urinary cytology and/or any invasive aspect on radiological examination and/or hydronephrosis ); * 2\. were ineligible for cisplatin-based chemotherapy(defined as meeting at least one of the following criteria: Eastern Cooperative Oncology Group \[ECOG\] performance status 2, creatinine clearance 30-60 mL/min, grade ≥2 audiometric hearing loss, grade ≥2 peripheral neuropathy, or New York Heart Association Class III heart failure); * 3\. had not received any systemic anti-tumor therapy; * 4\. Adequate organ function defined by study-specified laboratory tests; Hemoglobin ≥90 g/L; Hematological Absolute neutrophil count (ANC) ≥1.5×109 /L; Platelets ≥100×109 /L * 5\. No functional organic disease: T-BIL≤1.5×upper limit of normal (ULN); ALT andAST≤2.5×ULN; Serum creatinine≤2×ULN; endogenous creatinine clearance rate\>30ml/min * 6\. Agree to comply with scheduled visits, treatment plans, lab tests and any other required study procedures;
Exclusion criteria
* 1\. Patients who have received prior therapy of an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody; * 2\. Patients who are allergic to monoclonal antibodies or any of its excipients; * 3\. Patients who have received other systems for anti-tumor treatment (e. g., Steroid therapy, immunotherapy) within 4 weeks or enrolled in other clinical trials; * 4\. Patients who are pregnant or breastfeeding, or expecting to conceive; * 5\. Patients who have a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies); * 6\. Patients who have known active Hepatitis B or Hepatitis C; * 7\. Patients who have active autoimmune disease that has required systemic treatment in the past 2 years; * 8\. Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment; * 9\. Patients who have received prior radiation therapy to the bladder; * 10.Patients who have muscle invasive bladder cancer; * 11.Patients who have received allogeneic hematopoietic stem cell transplantation or solid organ transplantation; * 12.Patients who have a history of substance abuse or with a history of mental disorders; * 13.Patients who had other malignant tumors in the past five years that have not recovered except for curable tumors that have been cured including basal or squamous skin cancer, localized carcinoma in situ of the cervix or the breast and low-risk prostate cancer, etc. * 14.Patients who have active tuberculosis; * 15.Patients who have other serious and uncontrollable accompanying diseases that may affect compliance or interfere with the interpretation of results including active opportunistic infections or advanced (severe) infections, uncontrollable diabetes, cardiovascular disease (grade III or IV heart failure defined by the New York Heart Association classification, II degree atrioventricular block and above, myocardial infarction in the past 6 months, unstable arrhythmia or instability angina, cerebral infarction within 3 months, etc.) or lung disease (interstitial pneumonia, history of obstructive lung disease and symptomatic bronchospasm);
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pathological reponse rate | 30 days after surgery | ypT0N0 at surgical specimen，in the intention-to-treat population |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| pathological response rate | 30 days after surgery | ypT0 and ypT1 at surgical specimen，in the intention-to-treat population |
| perioperative complication rate | 30 days after surgery | the rate of perioperative complications are determined according to Clavien classification |
| objective response rate | 12 months after drug treatment | the proportion of patients with a confirmed complete response or partial response based on radiological examination before surgery per RECIST version 1.1 |
| disease free survival | 5 years after surgery or treatment | from surgery to any kind of recurrence including tumour bed, first metastasis, or death from any cause |
| overall survival | 5 years after enrollment | time from enrollment to death for any cause |
Countries
China
Outcome results
None listed